• Center on Health Equity & Access
  • Clinical
  • Health Care Cost
  • Health Care Delivery
  • Insurance
  • Policy
  • Technology
  • Value-Based Care

Dr Robert Gabbay: Diabetes Clinical Trials Should Be More Inclusive

Video

Robert A. Gabbay, MD, PhD, chief scientific and medical officer at the American Diabetes Association, explains why clinical trials need to be inclusive and how the Health Equity Now initiative is working to recruit more diverse populations with diabetes.

The Health Equity Now initiative is working to make clinical trials more inclusive, said Robert A. Gabbay, MD, PhD, chief scientific and medical officer at the American Diabetes Association.

Transcript

The new ADA and EASD Type 1 Diabetes Guidance mentions that most data are from White European populations. What is being done to improve data collection from other groups?

One of the important aspects of our Health Equity Now is to think about, how can we ensure that clinical trials are broadly representative of the population, and particularly people who were at greatest risk for complications in the development of diabetes. So we're working to make available clinical trial opportunities for individuals and, particularly on the advocacy perspective, advocating for more inclusive recruitment of individuals for studies related to diabetes treatments.

Related Videos
Laura Bobolts, PharmD, BCOP, senior vice president of clinical strategy and growth at OncoHealth
Adam Colburn, JD, associate vice president for congressional affairs, AMCP
Carla Nester, MD, MSA, FASN
AJMC Q&A with Jason Bellet, Dr Geoffrey Rutledge, and Dan Nardi
Richard Nowak, MD, MS, Yale School of Medicine
AMCP Recap 2025
Giulio Cossu, MD
Andrew Evens, DO
Lynae Darbes, PhD
Screenshot from interview with Andrew Evens, DO
Related Content
© 2025 MJH Life Sciences
AJMC®
All rights reserved.